Claim Missing Document
Check
Articles

Found 2 Documents
Search

Hubungan Pemberian Air Susu Ibu dengan Kejadian Kanker Payudara di Rumah Sakit Umum Daerah dr. Zainoel Abidin, Banda Aceh -, M. Riswan; Munawarah, Iffah
Cermin Dunia Kedokteran Vol 45, No 7 (2018): Onkologi
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (899.273 KB) | DOI: 10.55175/cdk.v45i7.638

Abstract

Latar belakang. Faktor – faktor yang dapat mempengaruhi kejadian kanker payudara adalah obesitas, usia melahirkan pertama, riwayat pemberian air susu ibu (ASI), perubahan gaya hidup, usia menarche pertama, dan usia menopause. Tujuan penelitian ini adalah untuk mengetahui hubungan pemberian ASI terhadap kejadian kanker payudara di Rumah Sakit Umum Daerah dr.Zainoel Abidin Banda Aceh. Metode. case control dengan accidental sampling yang melibatkan 64 orang. Data dikumpulkan menggunakan kuesioner. Hasil. Dari 32 pasien terdiagnosis kanker payudara, 21 pasien tidak memberikan ASI. Pada 32 pasien kontrol yang tidak menderita kanker hanya 2 pasien yang tidak memberikan ASI. Hasil analisis bivariat menggunakan chi-square menunjukkan hasil signifikan p = 0,000 (p ≤ 0,05). Simpulan. Terdapat hubungan bermakna antara riwayat pemberian ASI terhadap kejadian kanker payudara.Background. Risk factors of breast cancer were obesity, age of first delivery, breast feeding, lifestyle, age of menarche, and age of menopause. This study was to observe the relationship of breastfeeding and breast cancer incidence in dr. Zainoel Abidin Hospital Banda Aceh. Method. A case-control study with accidental sampling on 64 women. Data was collected using questionnaire. Result. Among 32 breast cancer patients, 21 patients did not breastfeed. And among 32 control patients, only 2 patients did not breastfeed. (p=0,000 ≤ 0,05). Conclusion. There is a significant correlation between breastfeeding and incidence of breast cancer. 
ACE inhibitors versus angiotensin receptor-neprilysin inhibitors for HFrEF management: A prospective cohort study from Indonesia Heriansyah, Teuku; Lestari, Nova D.; Hadi, Tjut F.; Novia, Rizki; Munawarah, Iffah; Taufiqurrahman, Taufiqurrahman; Yuvhendmindo, Shahcoga L.; Bashori, Ahmad A.
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.978

Abstract

Previous studies have reported that angiotensin receptor-neprilysin inhibitors (ARNI) are superior to angiotensin-converting enzyme inhibitors (ACEI) in treating heart failure with reduced ejection fraction (HFrEF). Unfortunately, previously published studies predominantly focused on Western populations, while the data remains insufficient in developing countries. The aim of this study was to compare the efficacies of ARNI and ACEI on patients with HFrEF in Indonesia. A prospective cohort study was conducted among heart failure patients at Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia. Both ACEI and ARNI each consisted of 40 subjects receiving standard treatment for heart failure. Left ventricular ejection fraction (LVEF), quality of life (QoL), suppression of tumorigenicity 2 (ST2), and troponin T were measured upon admission and at the end of the follow-up. In addition, the occurrence of major adverse cardiac events (MACE) was observed during 6 months of follow-up. Paired t-test was used to compare the outcomes of ACEI and ARNI. The results revealed that KKCQ score and LVEF were improved in both ARNI and ACEI groups (each with p<0.001). A higher KCCQ overall score was observed in the ARNI group in contrast to the ACEI group (p=0.01). ARNI demonstrated superior results in improving the ejection fraction as compared with ACEI (p=0.001). Troponin T and ST2 levels exhibited no significant difference between the two groups (p=0.07 and 0.286, respectively). MACE-associated mortality (p=0.696) and rehospitalization (p=0.955) were identical between both groups. In conclusion, ARNI was more efficacious than ACEI in improving the quality of life and left ventricular ejection fraction of patients with HFrEF. However, the efficacy was not significantly different in reducing the risk of MACE.